Adaptive Biotechnologies Corporation growth

Reported trailing growth, forward expectations and three-year compound growth rates.

Trailing growth

Year over year

Revenue: +55.9%
EBITDA: +81.5%
EBIT: +67.4%
EPS: +65.9%
Free cash flow: +66.7%
Operating cash flow: +68.3%

Forward estimates

Revenue: +5.4%
EBITDA: —
EPS: -21.0%

Three-year CAGR

Revenue: +14.3%
EBITDA: +76.8%
EBIT: +64.9%
Net income: +62.7%
EPS: +63.9%
Free cash flow: +50.5%

Latest available reported and market-derived figures. A dash means the source dataset does not currently cover that metric; it does not imply a zero value.